Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.
NCT ID: NCT01659346
Last Updated: 2017-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2016-02-29
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Endoscopic Variceal Ligation
Endoscopic Variceal Ligation every 3 weeks till eradication
Endoscopic Variceal Ligation
Endoscopic Variceal Ligation every 3 weeks till eradication.
Carvedilol
Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD
Carvedilol
Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Endoscopic Variceal Ligation
Endoscopic Variceal Ligation every 3 weeks till eradication.
Carvedilol
Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presence of large oesophageal varices or small with high risk
Exclusion Criteria
* Any Endoscopic Variceal Ligation or Sclerotherapy within last 3 months
* High risk gastric varices
* Any past history of Transhepatic Intrajugular Portosystemic Shunt or surgery for portal hypertension
* Significant cardio or pulmonary co-morbidity
* Any extrahepatic malignancy
* Patients with past history of variceal bleed
* Patients with non-tumor portal vein thrombosis
* Refusal to participate in the study
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institute of Liver and Biliary Sciences, India
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr Shakti P Choudhury, MD
Role: PRINCIPAL_INVESTIGATOR
Institute of Liver and Biliary Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Liver and Biliary Sciences
New Delhi, National Capital Territory of Delhi, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ILBS-HCC-01
Identifier Type: -
Identifier Source: org_study_id